Back to top
more

Corbus Pharmaceuticals (CRBP)

(Real Time Quote from BATS)

$52.51 USD

52.51
199,205

-0.20 (-0.38%)

Updated Sep 10, 2024 09:36 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock?

by Zacks Equity Research

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Corbus Pharmaceuticals (CRBP) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Corbus Pharmaceuticals (CRBP) closed at $7.64, marking a -0.52% move from the previous day.

Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) needs investors to pay close attention to the stock based on moves in the options market lately.

Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids

by Zacks Equity Research

CHMP gives positive opinion to Vertex's (VRTX) label expansion of Orkambi.

Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -23.81% and -34.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) in Focus: Stock Moves 6% Higher

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares rise 6% on the day, amid huge volumes.

    Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

      Vertex Completes Enrollment in Triple Combination Studies

      by Zacks Equity Research

      Vertex Pharmaceuticals (VRTX) completes enrollment in two phase III studies evaluating VX-659 triple combination regimen in CF patients. Data is expected in the fourth quarter of 2018.

        Vertex Inks Reimbursement Agreement for Orkambi in Australia

        by Zacks Equity Research

        Vertex Pharmaceuticals (VRTX) finalizes a reimbursement agreement with Australian government, which will improve the access to the drug.

          Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Misses Revenue Estimates

          by Zacks Equity Research

          Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -5.00% and -55.05%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

            Vertex's Shares Rally as a Rival's CF Candidate Disappoints

            by Zacks Equity Research

            Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.

              4 Best Marijuana Stocks to Play the Green Rush

              by Zacks Equity Research

              Given the increasing bullish environment, the movement to legalize marijuana has definitely picked up steam. Below are four cannabis-linked stocks that are poised to benefit from legalization.

                Corbus Pharmaceuticals (CRBP) in Focus: Stock Moves 10% Higher

                by Zacks Equity Research

                Corbus Pharmaceuticals (CRBP) was a big mover last session, as the company saw its shares rise 10% on the day.

                  Aerie Pharmaceuticals (AERI) Surges: Stock Moves 16.2% Higher

                  by Zacks Equity Research

                  Aerie Pharmaceuticals (AERI) was a big mover last session, as the company saw its shares rise more than 16% on the day amid huge volumes.

                    Flexion Therapeutics (FLXN) in Focus: Stock Moves 10.4% Higher

                    by Zacks Equity Research

                    Flexion Therapeutics (FLXN) shares rose more than 10% in the last trading session, amid huge volumes.

                      Infinity Pharmaceuticals, Inc. (INFI) in Focus: Stock Moves 12% Higher

                      by Zacks Equity Research

                      Infinity Pharmaceuticals, Inc. (INFI) saw its shares rise nearly 12% on the day.

                        Collegium Pharmaceutical (COLL) Looks Good: Stock Adds 6% in Session

                        by Zacks Equity Research

                        Collegium Pharmaceutical (COLL) shares rose 6% in the last trading session, amid huge volumes.

                          Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session

                          by Zacks Equity Research

                          Aldeyra Therapeutics (ALDX) saw a big move last session, as its shares jumped more than 34% on the day, amid huge volumes.

                            3 Reasons Momentum Stock Investors Will Love Corbus Pharmaceuticals Holdings (CRBP)

                            by Zacks Equity Research

                            Corbus Pharmaceuticals (CRBP) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.

                              Advanced Accelerator Applications (AAAP) in Focus: Stock Moves 7.5% Higher

                              by Zacks Equity Research

                              Advanced Accelerator Applications S.A. (AAAP) was a big mover last session, as the company saw its shares rise nearly 8% on the day.

                                Surging Earnings Estimates Signal Good News for Corbus Pharmaceuticals (CRBP)

                                by Zacks Equity Research

                                Corbus Pharmaceuticals (CRBP) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

                                  Arpita Dutt headshot

                                  Play the Marijuana Rush as First Marijuana-Focused ETF Launches

                                  by Arpita Dutt

                                  The medical marijuana industry has been gaining a lot of importance and attracting interest from investors over the last few quarters with companies like GW Pharma (GWPH) making headlines.

                                    Corbus Concludes Phase II study of Cystic Fibrosis Candidate

                                    by Zacks Equity Research

                                    Corbus Pharmaceuticals Holdings, Inc. (CRBP), recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF).